Literature DB >> 16954290

Effectiveness of cephalosporins in the sputum of patients with nosocomial bronchopneumonia.

Almos Klekner1, Kinga Bagyi, Laszlo Bognar, Attila Gaspar, Melinda Andrasi, Judit Szabo.   

Abstract

Nosocomial bronchopneumonia is a frequent complication in patients with chronic intratracheal intubation. Despite targeted antibiotic treatment, production of abundant bronchial secretion containing pathogen bacteria often tends to be chronic, and so mortality drastically increases. This problem led to an investigation of the penetration of five cephalosporin antibiotics into the sputum. Serum and sputum were collected from 24 chronically intubated patients having purulent nosocomial bronchopneumonia treated in an intensive care unit (ICU). Patients received the following doses intravenously every 24 h: five received 70 mg/kg of body weight cefuroxime, four received 110 mg/kg cefamandole, six received 80 mg/kg ceftriaxone, four received 80 mg/kg ceftazidime, and five received 80 mg/kg cefepime. Antibiotic concentrations in the serum and sputum were evaluated by capillary electrophoresis. MICs were determined for bacteria isolated from the purulent bronchial secretions. The mean levels of the cephalosporins in the sputum did not reach the MICs for the bacteria isolated from the same samples. Ceftriaxone was the only one of the investigated five cephalosporins that had a measurable concentration in the sputum (1.4 +/- 1.2 mg/liter). The low concentration of antibiotics in the purulent tracheobronchial secretion can be one of the many reasons for ineffective therapy of nosocomial bronchopneumonia in intubated patients in the ICUs. In the case of intubated or mechanically ventilated patients having chronic bronchopneumonia, determination of drug concentration in the bronchial secretion might be considered when selecting an antibiotic for treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16954290      PMCID: PMC1594714          DOI: 10.1128/JCM.00893-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia.

Authors:  R J Mangi; K M Peccerillo; J Ryan; C Berenson; T Greco; G Thornton; V T Andriole
Journal:  Diagn Microbiol Infect Dis       Date:  1992-07       Impact factor: 2.803

2.  Sputum and blood concentrations of cefuroxime in lower respiratory tract infection.

Authors:  C W Havard; R P Bax; T C Samanta; R M Pearson; W Brumfitt; J M Hamilton-Miller; C H Dash
Journal:  Thorax       Date:  1980-05       Impact factor: 9.139

3.  [Clinical studies and sputum levels of ceftriaxone once daily administration in respiratory tract infection].

Authors:  M Kuwabara; H Sasaki; H Fukuhara; H Arita; T Inamizu; K Sadamoto; T Kimura; K Yamane; M Shigemoto; M Kawamoto
Journal:  Jpn J Antibiot       Date:  1989-04

4.  Cefuroxime axetil in acute purulent exacerbations of chronic bronchitis.

Authors:  B I Davies; F P Maesen; J P Teengs
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

Review 5.  Nosocomial pneumonia. Diagnostic and therapeutic considerations.

Authors:  B A Cunha
Journal:  Med Clin North Am       Date:  2001-01       Impact factor: 5.456

6.  Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia.

Authors:  J C Lin; K M Yeh; M Y Peng; F Y Chang
Journal:  J Microbiol Immunol Infect       Date:  2001-06       Impact factor: 4.399

7.  Pulmonary complications of aneurysmal subarachnoid hemorrhage.

Authors:  Jonathan A Friedman; Mark A Pichelmann; David G Piepgras; Jon I McIver; L Gerard Toussaint; Robyn L McClelland; Douglas A Nichols; Fredric B Meyer; John L D Atkinson; Eelco F M Wijdicks
Journal:  Neurosurgery       Date:  2003-05       Impact factor: 4.654

8.  [Studies on penetration of cefepime into respiratory tract using broncho-alveolar lavage and sputum].

Authors:  C Arai; T Suzuki
Journal:  Jpn J Antibiot       Date:  1997-11

9.  The relationship between intraoperative contamination of the lower respiratory tract and postoperative chest infection.

Authors:  G G Morran; W McNaught; C S McArdle
Journal:  J Hosp Infect       Date:  1995-05       Impact factor: 3.926

10.  Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia.

Authors:  D Williams; M Perri; M J Zervos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-04       Impact factor: 3.267

View more
  5 in total

1.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Authors:  Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2022-06-29       Impact factor: 5.577

3.  Role of pathogenic oral flora in postoperative pneumonia following brain surgery.

Authors:  Kinga Bágyi; Angela Haczku; Ildikó Márton; Judit Szabó; Attila Gáspár; Melinda Andrási; Imre Varga; Judit Tóth; Almos Klekner
Journal:  BMC Infect Dis       Date:  2009-06-29       Impact factor: 3.090

4.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

Review 5.  Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.

Authors:  Joao Gonçalves-Pereira; Pedro Póvoa
Journal:  Crit Care       Date:  2011-09-13       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.